🔗 Permalink

Assignee profile:

Affimed GmbH

City:

Heidelberg

Country:

Germany

Published Applications:

Last publication date:

2024-09-05

Patent Grants:

Last grant date:

2024-09-03

Top Inventors for applications by Affimed GmbH

These are the the leading inventors for applications assigned to Affimed GmbH:

Martin TREDER 9 Heidelberg, Germany
Kristina ELLWANGER 7 Heidelberg, Germany
Uwe REUSCH 7 Maikammer, Germany
Ivica Fucek 5 Heidelberg, Germany

Erich Rajkovic 5 Heidelberg, Germany
Uwe Reusch 5 Heidelberg, Germany
Michael Tesar 5 Heidelberg, Germany
Joachim Koch 4 Heidelberg, Germany

Stefan Knackmuss 3 Plankstadt, Germany
Sergey KIPRIYANOV 3 Heidelberg, Germany
Thorsten ROSS 3 Edingen-Neckarhausen, Germany
Fabrice LE GALL 3 Edingen-Neckarhausen, Germany

Thorsten Ross 2 Heidelberg, Germany
Karin Hoffmann 2 Schwetzingen, Germany
Michael Damrat 2 Heidelberg, Germany
Michael WEICHEL 2 Bischofsheim, Germany

Michael Kluge 2 Heidelberg, Germany
Melvyn Little 2 Neckargemund, Germany
Erich Rajkovic 2 Schriessheim, Germany
Jens-Peter MARSCHNER 1 Seeheim-Jugenheim, Germany

Jens Pahl 1 Dossenheim, Germany
Adelheid Cerwenka 1 Heidelberg, Germany
Ivica FUCEK 1 Frankfurt/Main, Germany
Ivica Fucek 1 Hattersheim, Germany

Stefan Knackmuss 1 Planckstadt, Germany
Melvin LITTLE 1 Neckargemund, Germany
Affimed Therapeutics, AG 1 Heidelberg, Germany
Thomas MUELLER 1 Planckstadt, Germany

Erich RAJKOVIC 1 Schriesheim, Germany
Thorsten Ross 1 Heibelberg, Germany
Kristina Wanger 1 Heidelberg, Germany
Ivica Fucek 1 Frankfurt am Main, Germany

Recent patent applications by Affimed GmbH

Affimed GmbH based in Heidelberg, DE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-09-05

US20240294647A1

Chemistry; metallurgy

USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTS

#2 | 2023-06-22 ✅ Patent 12,076,384 granted on 2024-09-03

US20230190900A1

Human necessities

Bispecific EGFR/CD16 antigen-binding protein

#3 | 2021-08-19

US20210253698A1

Chemistry; metallurgy

USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTS

#4 | 2020-12-31 ✅ Patent 11,510,972 granted on 2022-11-29

US20200405833A1

Human necessities

Bispecific EGFR/CD16 antigen-binding protein

#5 | 2020-04-09 ✅ Patent 11,001,633 granted on 2021-05-11

US20200109202A1

Chemistry; metallurgy

NK cell engaging antibody fusion constructs

#6 | 2020-01-09 ✅ Patent 11,535,672 granted on 2022-12-27

US20200010547A1

Chemistry; metallurgy

Combination of an anti-CD16A antibody with a cytokine

#7 | 2019-11-14 ✅ Patent 11,180,558 granted on 2021-11-23

US20190345249A1

Chemistry; metallurgy

Tandem diabody for CD16A-directed NK-cell engagement

#8 | 2019-02-07 ✅ Patent 11,572,415 granted on 2023-02-07

US20190040155A1

Chemistry; metallurgy

Multivalent FV antibodies

#9 | 2018-03-29 ✅ Patent 11,167,029 granted on 2021-11-09

US20180085456A1

Human necessities

Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy

#10 | 2015-08-06 ✅ Patent 9,701,750 granted on 2017-07-11

US20150218275A1

Chemistry; metallurgy

Anti-CD16 binding molecules

#11 | 2013-05-09 ✅ Patent 9,226,962 granted on 2016-01-05

US20130115213A1

Human necessities

Human CD3-specific antibody with immunosuppressive properties

#12 | 2009-08-27 ✅ Patent 9,035,026 granted on 2015-05-19

US20090214574A1

Chemistry; metallurgy

Anti-CD16 binding molecules

Also check out Affimed GmbH's (Heidelberg, Germany) applicant profile with 12 patent applications submitted.

AssigneeID:

156837 ⎘